Tertiary lymphoid structures generate and propagate anti-tumor antibody-producing plasma cells in renal cell cancer - Archive ouverte HAL Access content directly
Journal Articles Immunity Year : 2022

Tertiary lymphoid structures generate and propagate anti-tumor antibody-producing plasma cells in renal cell cancer

(1) , (2, 3) , (2) , (1) , (1) , (1) , (1) , (4, 5) , (1) , (1) , (1) , (1) , (1, 2, 3, 6, 4, 5) , (7) , (4) , (8) , (8) , (8) , (4) , (9) , (2, 6, 3, 1) , (1) , (1)
1
2
3
4
5
6
7
8
9
Maxime Meylan
Pierre Laurent-Puig

Abstract

The presence of intratumoral tertiary lymphoid structures (TLS) is associated with positive clinical outcomes and responses to immunotherapy in cancer. Here, we used spatial transcriptomics to examine the nature of B cell responses within TLS in renal cell carcinoma (RCC). B cells were enriched in TLS, and therein, we could identify all B cell maturation stages toward plasma cell (PC) formation. B cell repertoire analysis revealed clonal diversification, selection, expansion in TLS, and the presence of fully mature clonotypes at distance. In TLS+ tumors, IgG- and IgA-producing PCs disseminated into the tumor beds along fibroblastic tracks. TLS+ tumors exhibited high frequencies of IgG-producing PCs and IgG-stained and apoptotic malignant cells, suggestive of anti-tumor effector activity. Therapeutic responses and progression-free survival correlated with IgG-stained tumor cells in RCC patients treated with immune checkpoint inhibitors. Thus, intratumoral TLS sustains B cell maturation and antibody production that is associated with response to immunotherapy, potentially via direct anti-tumor effects.
Fichier principal
Vignette du fichier
PIIS1074761322000814.pdf (9.57 Mo) Télécharger le fichier
Loading...

Dates and versions

inserm-03653110 , version 1 (27-04-2022)

Identifiers

Cite

Maxime Meylan, Florent Petitprez, Etienne Becht, Antoine Bougoüin, Guilhem Pupier, et al.. Tertiary lymphoid structures generate and propagate anti-tumor antibody-producing plasma cells in renal cell cancer. Immunity, 2022, 55 (3), pp.527-541.e5. ⟨10.1016/j.immuni.2022.02.001⟩. ⟨inserm-03653110⟩
82 View
8 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More